Imeth

Methotrexate, the active ingredient in Imeth, is an antimetabolite presented as a subcutaneous formulation for subcutaneous use. It is employed in the management of rheumatoid arthritis, psoriasis, certain leukemias and lymphomas, and ectopic pregnancy, providing disease‑modifying and antineoplastic effects.

GNH USA supplies Imeth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution originating from the European Union market. The product conforms to EU regulatory standards and is manufactured under GMP conditions.

Methotrexate is used across several disease categories, primarily as a disease‑modifying antirheumatic drug and an antineoplastic agent.

Rheumatoid arthritis: reduces joint inflammation and slows structural damage. Psoriasis: limits skin cell proliferation and improves plaque severity. Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. Non‑Hodgkin lymphoma: suppresses tumor growth by inhibiting DNA synthesis. Ectopic pregnancy: halts trophoblastic tissue development to facilitate medical management.

Methotrexate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration (stomatitis). - Elevated liver enzymes. - Mild leukopenia or thrombocytopenia.

Serious or Rare Side Effects: - Severe hepatotoxicity or hepatic fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute renal failure. - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome). - Opportunistic infections due to immunosuppression.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

Liver monitoring: perform baseline and periodic liver function tests. Blood count monitoring: check complete blood count regularly. Pregnancy avoidance: contraindicated in pregnancy (Category X). Renal function: adjust dose or avoid in severe renal impairment. Drug interactions: review concomitant medications for potential toxicity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes; awareness of interaction severity guides clinical management.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Sulfonamide antibiotics and trimethoprim: potentiate hematologic suppression. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or cyclosporine: additive immunosuppressive effect. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Alcohol or hepatotoxic agents: increase risk of liver injury.